Delivery Order SPE2DB22D2206-SPE2DB25FJB21
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $34,908 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 14, 2025, with performance to take place at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting AmerisourceBergen's demonstrated capability to compete in the...
- The Defense Logistics Agency awarded a $23,272.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C (40 gram/400 ml vial), with an ultimate completion date of August 13, 2025. This is an unset-aside, competitively awarded contract that will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. As a child order under a larger contract vehicle, this delivery order represents a single transaction within AmerisourceBergen's extensive pharmaceutical...
- The Defense Logistics Agency awarded a $11,636.00 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) therapy used to treat various immunodeficiency and autoimmune conditions, making it a critical...
- The Defense Logistics Agency awarded a $7,080.84 delivery order contract to AmerisourceBergen Drug Corp for GAMUNEX-C (Immune Globulin Intravenous [Human]), a specialized pharmaceutical product supplied in 20 gram/200 milliliter vials. This firm fixed-price, non-set-aside contract is scheduled for completion by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine replenishment order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of GAMUNEX-C 5 gram/50 milliliter vials valued at $3,036.70. This non-competitive delivery order, which must be completed by August 15, 2025, represents a firm fixed-price transaction under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- This is a $115,417.92 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of GAMUNEX-C 40 gram/400 ml vials, a pharmaceutical product. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical for delivering a comprehensive range of medical commodities to support...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $57,708.96 to AmerisourceBergen Drug Corp for the supply of 40-gram/400-mL vials of the pharmaceutical product GAMUNEX-C. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 between the DLA and AmerisourceBergen for the delivery of a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract...
- The Defense Logistics Agency awarded a $46,544 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of GAMUNEX-C 40 gram/400 mL vials on July 24, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999 valuation through December 2026. The product will...
- This is a $42,485.04 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of GAMUNEX-C 20 gram/200 ml vials. The contract has an ultimate completion date of March 7, 2025. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,315.12 contract is for the supply of GAMUNEX-C 40 gram/400 ml vials to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract has an ultimate completion date of January 12, 2024. This delivery order is...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJB21Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,178.10 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order was issued without a set-aside designation, reflecting open competition among qualified vendors. This delivery order represents a child contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs and other federal healthcare systems. GAMUNEX-C is an immune globulin preparation used for immunodeficiency treatment, consistent with the company's extensive portfolio of specialty medications, biologics, and vaccines delivered through its federal medical supply contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $41.2k | 7/24/25 |